Early Intervention Center

for Autism and Developmental Disorders



مركـز التـدخــل الـمبـكــر للتـوحـّد واضطرابـات الـنـمــو

Director's Report on Developmental Progress Assessment

Date of Visit: 27-04-2025

Case Names:

Omar DmourSanad Dmour

Date of Birth (Both): 30-06-2014

Gender: Male **Guardian:** Abdelaziz

Assessment

Omar and Sanad Dmour, twin siblings (non-identical), were assessed at our center on 27-04-2025.

Both children demonstrate:

- Information Processing Delays
- Intellectual Developmental Delays
- Acquired features of Autism likely resulting from developmental impact associated with mitochondrial function disturbances.

While Sanad has a confirmed genetic variant identified in previous testing, it cannot be conclusively determined that this is the sole cause of his clinical features.

Both twins display varying severity:

- Sanad presents with a more severe intellectual and developmental phenotype compared to Omar.
- This difference could be attributed to distinct underlying genetic expressions, environmental factors, or mitochondrial functional variation.

The findings outlined below represent an analysis of their current developmental profiles for intervention planning and not a definitive medical diagnosis.

Recommended Plan

- 1) Development Protocol for Information Processing
 - Continue the cognitive and behavioral development protocol focused on enhancing information processing, executive functioning, and cognitive resilience.
 - **Duration:** 3–4 months
 - **Reevaluation:** In person after protocol completion to reassess developmental gains and adjust interventions accordingly.





Early Intervention Center

for Autism and Developmental Disorders



2) Recommended Tests:

Omar Dmour

• Precision Health Analysis - Neurazon (Canada):

A detailed analysis to investigate potential underlying causative factors.

Sample: Saliva

Turnaround: 4 months business days.

• Neuronal Growth Factors Absorption Analysis – Neurazon (Canada):

Screening to evaluate the absorption of critical neuronal growth factors essential for cognitive and

neurological development.

Sample: Hair

Turnaround: 2 months business days. **Frequency:** Repeated every 6–12 months.

• Functional Urine Analysis - Neurazon (Canada):

Analysis focusing on mitochondrial, metabolic, and neurotransmitter pathways related to cognitive

function. **Sample:** Urine

Turnaround: 3 months business days. **Frequency:** Repeated every 6–12 months.

EIGADD

Sanad Dmour

Precision Health Analysis – Neurazon (Canada):

To investigate further genetic or functional factors contributing to the more severe clinical presentation.

Sample: Saliva

Turnaround: 4 months business days.

Functional Urine Analysis – Neurazon (Canada):

Targeted analysis of functional biochemical pathways supporting mitochondrial and neuronal function.

Sample: Urine

Turnaround: 3 months business days. **Frequency:** Repeated every 6–12 months.

Gut Intolerance Analysis – Neurazon (Canada):

Screening to identify potential food intolerances affecting gut-brain axis health and behavior.

Sample: Hair

Turnaround: 2 months business days. **Frequency:** Repeated every 6–12 months.

• Neuronal Growth Factors Absorption Analysis – Neurazon (Canada):

Analysis of neuronal nutrient absorption supporting brain growth and developmental progress.

Sample: Hair

Turnaround: 2 months business days. **Frequency:** Repeated every 6–12 months.





Early Intervention Center

for Autism and Developmental Disorders



مركـز التـدخــل الـمبـكــر للتـوحـّد واضطرابـات الـنـمــو

3) Recommended Therapy

• Mitotherapy Sessions:

- o **Frequency:** 2–3 sessions initially.
- Purpose: Support mitochondrial function, enhance energy metabolism in brain cells, and promote better cognitive and behavioral outcomes.

Follow-Up Plan

Reassessment:

After 3–4 months of therapy to measure developmental progress and functional improvements.

• Continuous Monitoring:

Detailed documentation of therapy sessions, behavioral changes at home, and school performance is essential to guide next steps.

• Important Note:

This report provides a developmental and functional evaluation for therapeutic purposes and is not considered a final medical diagnosis. Both children remain open to continued developmental progress with structured, individualized support.

Issued by: EICADD Center Date: 27-04-2025

Signature:

EICADD Center Director





